DIA: Driving Insights to Action
Science:Life Sciences
Do changes in clinical research, driven by emerging technology, change what we mean by “evidence”? “It’s not necessarily ‘trials versus real world evidence’–that is not particularly helpful because either type of evidence, either type of data, has its place and is complementary,” explains Mr. Michael Seewald, WorldWide Head of the Center of Excellence for Real World Evidence, Novartis Pharma, and member of DIA’s Future of Evidence Workshop program committee. “The exciting development is in developing data sources over a timeframe of decades that at some point will revolutionize healthcare in a respective therapy area.”
AI Research Can Optimize Clinical/Operational Effectiveness
Has Joining ICH Accelerated Innovation in China?
Pricing Pitfalls in Prescription Drug Advertising
MID-NET Among PMDA’s First Steps Into RWE
Regulatory Science 2019: Leading or Holding Back Innovation?
23andMe: Information Empowering Patient Action
The Patient’s Most Engaging Question: Why?
EUnetHTA: Post-Launch Critical for Comparative Data
HSA Harmonizing Culture and Science in Singapore
Promoting Patient-Centric Business: MedComm in Latin America
Separate but Equal: Regulatory & Pricing Assessments in EU
Genetics Leading Modern Revolution in Cancer Care
Automation No Substitute for Scientific Leadership
R2D2 & C-17 New Landmarks in Canada’s Collaborative Pathways
Advanced Therapies Moving Upon Combination Platforms
Challenges in Generic Drug Safety & Surveillance
Interview with a DIA 2018 Patient Scholar
Novel Approaches to PV Collaboration
Advancing the Science of Study Endpoints
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths